Raymond James Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target of $42
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Gary Nachman has initiated coverage on Pacira BioSciences (NASDAQ:PCRX) with an Outperform rating and set a price target of $42.
December 20, 2023 | 11:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James initiated coverage on Pacira BioSciences with an Outperform rating and a price target of $42, which may positively influence the stock's performance.
Analyst coverage, especially with an Outperform rating, tends to signal confidence in a company's future performance and can lead to increased investor interest. The price target of $42 suggests a positive outlook for the stock, which may result in a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100